Skip to main content

COVID-19 UPDATES >

Title

COVID19 Response

The U.S. continues to see its highest number of novel coronavirus cases to date. Dr. Paul Stoffels, Vice Chairman of the Executive Committee, Chief Scientific Officer, Johnson & Johnson, and other healthcare professionals share tips on staying protected and quarantining effectively.

For COVID-19-Related Media Inquiries, click here.

News Releases

Johnson & Johnson Announces
Agreement in Principle with
Gavi to Supply Janssen's COVID-19
Vaccine Candidate to Lower-Income Countries in 2021

Johnson & Johnson Phase 3
COVID-19 Vaccine Trial ENSEMBLE
Fully Enrolled

Johnson & Johnson Announces
the Initiation of a Rolling
Submission for its Single-dose
Janssen COVID-19 Vaccine Candidate with Health Canada

Johnson & Johnson Announces
Initiation of Rolling Submission
for its Single-dose Janssen
COVID-19 Vaccine Candidate
with the European Medicines Agency

Johnson & Johnson Initiates
Second Global Phase 3
Clinical Trial of its Janssen
COVID-19 Vaccine Candidate

Johnson & Johnson Prepares
to Resume Phase 3
ENSEMBLE Trial of its Janssen
COVID-19 Vaccine Candidate
in the U.S.

Johnson & Johnson
Temporarily Pauses
All Dosing in Our
Janssen COVID-19
Vaccine Candidate
Clinical Trials

Johnson & Johnson
Initiates Pivotal
Global Phase 3
Clinical Trial of
Janssen’s COVID-19
Vaccine Candidate

Biopharm Leaders
Unite to Stand
With Science

Johnson & Johnson
Announces Agreement
with U.S. Government
for 100 Million Doses of
Investigational COVID-19 Vaccine

Johnson & Johnson
Announces Acceleration
of its COVID-19
Vaccine Candidate; Phase 1/2a
Clinical Trial to Begin
in Second Half of July

Johnson & Johnson
Announces a Lead
Vaccine Candidate for
COVID-19; Landmark New
Partnership with U.S.
Department of Health & Human Services;
and Commitment to Supply One Billion
Vaccines Worldwide for
Emergency Pandemic Use

Lack of Evidence to Support Use of Darunavir-based Treatments for SARS-CoV-2

Johnson & Johnson to
Expand
Partnership with
U.S. Department of
Health
& Human Services to
Accelerate the Discovery of
Potential
COVID-19
Treatment

Johnson & Johnson
Announces
Collaboration
with the Beth Israel
Deaconess Medical Center
to
Accelerate COVID-19
Vaccine
Development

Our Response to the Pandemic

Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, answers the latest questions about Johnson & Johnson's investigational vaccine candidate

Johnson & Johnson’s response
to COVID-19

The 5 stages of COVID-19 vaccine development:
What you need to know about how a clinical trial works

4 Facts About
Johnson & Johnson’s Investigational COVID-19 Vaccine

Our commitment
to frontline
health workers battling COVID-19

Our commitment
to employees
during the global pandemic

Infographic: Mobilizing our resources to find solutions for COVID-19

Six Impactful Ways Johnson & Johnson is Helping in the Fight Against COVID-19

Six ways Johnson &
Johnson is
helping support
the COVID-19 relief
efforts

Ensuring stable access to medicines, products, devises and solutions

How our supply chain is
responding
to the
COVID-19 pandemic

COVID-19 and Our Medicines:
An Ethical Framework
for Decision-Making